ALPMF
Price
$9.85
Change
-$0.95 (-8.80%)
Updated
Oct 17 closing price
Capitalization
19.05B
GRFS
Price
$9.65
Change
-$0.10 (-1.03%)
Updated
Oct 17 closing price
Capitalization
8.3B
18 days until earnings call
Interact to see
Advertisement

ALPMF vs GRFS

Header iconALPMF vs GRFS Comparison
Open Charts ALPMF vs GRFSBanner chart's image
Astellas Pharma
Price$9.85
Change-$0.95 (-8.80%)
Volume$100
Capitalization19.05B
Grifols SA
Price$9.65
Change-$0.10 (-1.03%)
Volume$442.77K
Capitalization8.3B
ALPMF vs GRFS Comparison Chart in %
ALPMF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ALPMF vs. GRFS commentary
Oct 19, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALPMF is a Hold and GRFS is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 19, 2025
Stock price -- (ALPMF: $9.85 vs. GRFS: $9.65)
Brand notoriety: ALPMF and GRFS are both not notable
Both companies represent the Pharmaceuticals: Major industry
Current volume relative to the 65-day Moving Average: ALPMF: 3% vs. GRFS: 70%
Market capitalization -- ALPMF: $19.05B vs. GRFS: $8.3B
ALPMF [@Pharmaceuticals: Major] is valued at $19.05B. GRFS’s [@Pharmaceuticals: Major] market capitalization is $8.3B. The market cap for tickers in the [@Pharmaceuticals: Major] industry ranges from $719.7B to $0. The average market capitalization across the [@Pharmaceuticals: Major] industry is $94.09B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALPMF’s FA Score shows that 1 FA rating(s) are green whileGRFS’s FA Score has 1 green FA rating(s).

  • ALPMF’s FA Score: 1 green, 4 red.
  • GRFS’s FA Score: 1 green, 4 red.
According to our system of comparison, ALPMF is a better buy in the long-term than GRFS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALPMF’s TA Score shows that 5 TA indicator(s) are bullish while GRFS’s TA Score has 5 bullish TA indicator(s).

  • ALPMF’s TA Score: 5 bullish, 3 bearish.
  • GRFS’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, ALPMF is a better buy in the short-term than GRFS.

Price Growth

ALPMF (@Pharmaceuticals: Major) experienced а -8.20% price change this week, while GRFS (@Pharmaceuticals: Major) price change was +3.54% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Major industry was +0.16%. For the same industry, the average monthly price growth was +1.84%, and the average quarterly price growth was +19.16%.

Reported Earning Dates

GRFS is expected to report earnings on Nov 06, 2025.

Industries' Descriptions

@Pharmaceuticals: Major (+0.16% weekly)

The Major Pharmaceuticals industry includes companies that are involved in various processes of creating drugs to treat/prevent diseases. These companies engage in research, testing and manufacturing, as well as the distribution of pharmaceuticals into markets. Johnson & Johnson, Merck & Co., Inc., Pfizer Inc. and Novartis are among the largest companies in this category.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ALPMF($19B) has a higher market cap than GRFS($8.3B). ALPMF has higher P/E ratio than GRFS: ALPMF (52.65) vs GRFS (18.83). GRFS YTD gains are higher at: 31.892 vs. ALPMF (-0.122). ALPMF has higher annual earnings (EBITDA): 270B vs. GRFS (1.62B). ALPMF has more cash in the bank: 329B vs. GRFS (566M). GRFS has less debt than ALPMF: GRFS (8.82B) vs ALPMF (927B). ALPMF has higher revenues than GRFS: ALPMF (1.77T) vs GRFS (7.45B).
ALPMFGRFSALPMF / GRFS
Capitalization19B8.3B229%
EBITDA270B1.62B16,687%
Gain YTD-0.12231.892-0%
P/E Ratio52.6518.83280%
Revenue1.77T7.45B23,798%
Total Cash329B566M58,127%
Total Debt927B8.82B10,511%
FUNDAMENTALS RATINGS
ALPMF vs GRFS: Fundamental Ratings
ALPMF
GRFS
OUTLOOK RATING
1..100
5031
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
21
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10084
PRICE GROWTH RATING
1..100
6149
P/E GROWTH RATING
1..100
4692
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ALPMF's Valuation (7) in the null industry is in the same range as GRFS (21) in the Pharmaceuticals Major industry. This means that ALPMF’s stock grew similarly to GRFS’s over the last 12 months.

ALPMF's Profit vs Risk Rating (100) in the null industry is in the same range as GRFS (100) in the Pharmaceuticals Major industry. This means that ALPMF’s stock grew similarly to GRFS’s over the last 12 months.

GRFS's SMR Rating (84) in the Pharmaceuticals Major industry is in the same range as ALPMF (100) in the null industry. This means that GRFS’s stock grew similarly to ALPMF’s over the last 12 months.

GRFS's Price Growth Rating (49) in the Pharmaceuticals Major industry is in the same range as ALPMF (61) in the null industry. This means that GRFS’s stock grew similarly to ALPMF’s over the last 12 months.

ALPMF's P/E Growth Rating (46) in the null industry is somewhat better than the same rating for GRFS (92) in the Pharmaceuticals Major industry. This means that ALPMF’s stock grew somewhat faster than GRFS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ALPMFGRFS
RSI
ODDS (%)
Bullish Trend 3 days ago
55%
Bullish Trend 3 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
51%
Bullish Trend 3 days ago
71%
Momentum
ODDS (%)
Bearish Trend 3 days ago
59%
Bearish Trend 3 days ago
68%
MACD
ODDS (%)
N/A
Bullish Trend 3 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 3 days ago
50%
Bullish Trend 3 days ago
73%
TrendMonth
ODDS (%)
Bearish Trend 3 days ago
50%
Bearish Trend 3 days ago
71%
Advances
ODDS (%)
Bullish Trend 24 days ago
52%
Bullish Trend 4 days ago
71%
Declines
ODDS (%)
N/A
Bearish Trend 10 days ago
75%
BollingerBands
ODDS (%)
Bullish Trend 3 days ago
60%
Bullish Trend 3 days ago
77%
Aroon
ODDS (%)
Bullish Trend 6 days ago
40%
Bearish Trend 6 days ago
58%
View a ticker or compare two or three
Interact to see
Advertisement
ALPMF
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
GRFS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
JFNCX63.200.38
+0.60%
Janus Henderson Global Life Sciences C
FDCPX135.910.59
+0.44%
Fidelity Select Tech Hardware
BHCHX19.630.04
+0.21%
Baron Health Care Instl
RLBGX39.040.04
+0.10%
American Funds American Balanced R6
MSQLX11.730.01
+0.09%
Morgan Stanley Inst International Eq L

ALPMF and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALPMF has been loosely correlated with ALPMY. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if ALPMF jumps, then ALPMY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALPMF
1D Price
Change %
ALPMF100%
-8.81%
ALPMY - ALPMF
38%
Loosely correlated
+1.62%
JNJ - ALPMF
13%
Poorly correlated
+0.57%
GRFS - ALPMF
10%
Poorly correlated
-1.03%
AZNCF - ALPMF
8%
Poorly correlated
+1.04%
ABBV - ALPMF
5%
Poorly correlated
+1.19%
More

GRFS and

Correlation & Price change

A.I.dvisor indicates that over the last year, GRFS has been closely correlated with GIKLY. These tickers have moved in lockstep 68% of the time. This A.I.-generated data suggests there is a high statistical probability that if GRFS jumps, then GIKLY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GRFS
1D Price
Change %
GRFS100%
-1.03%
GIKLY - GRFS
68%
Closely correlated
N/A
GIFOF - GRFS
37%
Loosely correlated
N/A
GILD - GRFS
29%
Poorly correlated
+4.21%
PFE - GRFS
28%
Poorly correlated
+1.16%
BIIB - GRFS
28%
Poorly correlated
+0.52%
More